Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 120 participants.

Also called NCT01664637

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Tranzyme, Inc. (from the registry)
Registry
  • NCT NCT01664637
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Poland (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01664637. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
Acronym
DIGEST
Condition
Diabetic Gastroparesis
Intervention (Drug)
10 mg TZP-102
Intervention (Drug)
Placebo
Lead sponsor
Tranzyme, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01664637
Content hash
c2d5f8bc13c84935d87193c693a87bda71454df8fcfb4954e37d1e926e6c60ef